Xeris Biopharma (NASDAQ:XERS) Shares Up 4.7% – Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) shares were up 4.7% during mid-day trading on Friday . The company traded as high as $4.40 and last traded at $4.32. Approximately 971,657 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,820,396 shares. The stock had previously closed at $4.13.

Analysts Set New Price Targets

Several brokerages have recently weighed in on XERS. HC Wainwright reissued a “buy” rating and set a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th.

Xeris Biopharma Price Performance

The firm has a market capitalization of $628.53 million, a price-to-earnings ratio of -9.37 and a beta of 2.32. The stock has a 50 day moving average price of $3.54 and a two-hundred day moving average price of $3.24.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of XERS. China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after buying an additional 3,447 shares during the period. GPS Wealth Strategies Group LLC grew its stake in shares of Xeris Biopharma by 6.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock worth $227,000 after acquiring an additional 3,900 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in shares of Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Prudential Financial Inc. raised its stake in shares of Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock valued at $125,000 after acquiring an additional 7,000 shares in the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.